The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 20, 2020
Filed:
Feb. 19, 2016
Abivax, Paris, FR;
Centre National DE LA Recherche Scientifique, Paris, FR;
Institut Curie, Paris, FR;
Universite DE Montpellier, Montpellier, FR;
Didier Scherrer, Castelnau le Lez, FR;
Aude Garcel, Le Cres, FR;
Noelie Campos, Le Cres, FR;
Jamal Tazi, Clapiers, FR;
Audrey Vautrin, Castelnau le Lez, FR;
Florence Mahuteau, Saint Remy les Chevreuses, FR;
Romain Najman, L'Hay-les-Roses, FR;
Pauline Fornarelli, Villebon sur Yvette, FR;
ABIVAX, Paris, FR;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris, FR;
INSTITUT CURIE, Paris, FR;
UNIVERSITE DE MONTPELLIER, Montpellier, FR;
Abstract
The present invention relates to a quinoline derivative of formula (I) or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored. The present invention further relates to a quinoline derivative of formula (I) as defined in claim, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, for which an ineffectiveness or a decline in a prior anti-retroviral treatment effectiveness has been stated and to a quinoline derivative of formula (I) as defined above, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, wherein the patient is infected by a drug-resistant viral strain, and more particularly by a drug-resistant HIV strain.